by Francisca Peixoto | Apr 22, 2024 | Uncategorized
Our portfolio company Ochre Bio just signed a $1B partnership with Boehringer Ingelheim. Boehringer is a top 20 biopharmaceutical company by revenue and is the world’s largest private biopharma company, it is also a leader in liver disease R&D and has substantial...
by Francisca Peixoto | Apr 5, 2024 | Uncategorized
Our portfolio company InCephalo just appointed Dr. Lorenz Mayr as their new Chair. As the new Chairman of InCephalo, Dr. Lorenz Mayr brings his incredible experience in big names such as Bayer, Novartis, AstraZeneca, and Syncona. We, here at LifeLink Ventures, can’t...
by Francisca Peixoto | Apr 5, 2024 | Uncategorized
The CEO of our portfolio company Ochre Bio just did an interview with Judy Khan Shaw from the New York Stock Exchange. As published by NYSE on LinkedIn here: “Ochre Bio is on a mission to revolutionize liver disease treatment. Co-Founder + CEO Jack O’Meara...
by Francisca Peixoto | Mar 19, 2024 | Uncategorized
Our CEO and Co-founder, Francisca Peixoto, was a moderator, on March 19th, 2024, in a panel at this year’s BIO-EUROPE SPRING. The panel theme was named “In sync or offbeat: are the expectations of VCs and entrepreneurs aligned?”. This panel had the...
by Francisca Peixoto | Jan 5, 2024 | Uncategorized
As we start the new year, LifeLink Ventures releases its 2023 Annual Biotech Report. We wish to connect private investors with emerging technologies that address global health challenges. To do so, first we must bring our investors closer to the biotech world. Learn...
by Francisca Peixoto | Dec 20, 2023 | Uncategorized
Our portfolio company Eveliqure Biotechnologies announces, on December 18th 2023, that it has launched a Clinical Trial for their Shigellosis and ETEC vaccine in Bangladesh. Eveliqure is a clinical-stage Austrian biotechnology company that has developed a proprietary...
